Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 15.65M | 12.97M | 10.92M | 9.47M | 8.20M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 75.88M | 58.69M | 44.12M | 38.18M | 37.16M |
Operating Income | -75.88M | -58.69M | -44.12M | -38.18M | -37.16M |
Income Before Tax | -67.20M | -49.02M | -33.82M | -32.09M | -31.74M |
Income Tax Expenses | 18.00K | -- | -- | -- | -- |
Earnings from Continuing Operations | -67.22M | -49.02M | -33.82M | -32.09M | -31.74M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -67.22M | -49.02M | -33.82M | -32.09M | -31.74M |
EBIT | -75.88M | -58.69M | -44.12M | -38.18M | -37.16M |
EBITDA | -75.81M | -58.64M | -44.09M | -38.15M | -- |
EPS Basic | -1.17 | -0.86 | -0.60 | -0.64 | -0.66 |
Normalized Basic EPS | -0.73 | -0.54 | -0.37 | -0.40 | -0.41 |
EPS Diluted | -1.17 | -0.86 | -0.60 | -0.64 | -0.66 |
Normalized Diluted EPS | -0.73 | -0.54 | -0.37 | -0.40 | -0.41 |
Average Basic Shares Outstanding | 57.25M | 56.80M | 56.52M | 50.19M | 48.39M |
Average Diluted Shares Outstanding | 57.25M | 56.80M | 56.52M | 50.19M | 48.39M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |